Technology Acquisition Agreement - Additional Information (Detail) - USD ($)
|
1 Months Ended |
12 Months Ended |
May. 31, 2014 |
Jun. 30, 2007 |
Dec. 31, 2015 |
| Technology Acquisition Agreement [Line Items] |
|
|
|
| Payment expensed as in-process research and development |
|
$ 650,000
|
|
| Mallinckrodt Plc [Member] | Patented Technology [Member] |
|
|
|
| Technology Acquisition Agreement [Line Items] |
|
|
|
| Expected expiration of patent right |
|
|
2030
|
| Mallinckrodt Plc [Member] | Rights and Patents Acquired from Questcor Pharmaceuticals Inc [Member] | Maximum [Member] |
|
|
|
| Technology Acquisition Agreement [Line Items] |
|
|
|
| Milestone payments contingent amount |
|
|
$ 51,500,000
|
| Development Target One [Member] | Rights and Patents Acquired from Questcor Pharmaceuticals Inc [Member] |
|
|
|
| Technology Acquisition Agreement [Line Items] |
|
|
|
| Milestone payment |
$ 500,000
|
|
|
| Development targets description |
|
|
Upon the initiation of the first patient dosing in the Company's Phase 3 clinical trial for EVK-001
|
| Development Target Two And Three [Member] | Mallinckrodt Plc [Member] | Maximum [Member] |
|
|
|
| Technology Acquisition Agreement [Line Items] |
|
|
|
| Milestone payments contingent amount |
|
|
$ 4,500,000
|
| Development Target Two [Member] | Mallinckrodt Plc [Member] |
|
|
|
| Technology Acquisition Agreement [Line Items] |
|
|
|
| Development targets description |
|
|
Upon the FDA’s acceptance for review of an NDA for EVK-001
|
| Milestone payments contingent amount |
|
|
$ 1,500,000
|
| Development Target Three [Member] | Mallinckrodt Plc [Member] |
|
|
|
| Technology Acquisition Agreement [Line Items] |
|
|
|
| Development targets description |
|
|
Upon the FDA's approval of EVK-001
|
| Milestone payments contingent amount |
|
|
$ 3,000,000
|
| Development Target Four [Member] | Mallinckrodt Plc [Member] | Patented Technology [Member] |
|
|
|
| Technology Acquisition Agreement [Line Items] |
|
|
|
| Development targets description |
|
|
Depend on EVK-001's commercial success and will only apply if EVK-001 receives regulatory approval. In addition, the Company will be required to pay to Mallinckrodt a low single digit royalty on net sales of EVK-001.
|
| Milestone payments contingent amount |
|
|
$ 47,000,000
|